anastrozole sanoswiss 1 mg apvalkotās tabletes
sanoswiss uab, lithuania - anastrozols - apvalkotā tablete - 1 mg
anastrozole accord 1 mg apvalkotās tabletes
accord healthcare b.v., netherlands - anastrozols - apvalkotā tablete - 1 mg
axastrol 1 mg apvalkotās tabletes
grindeks, as, latvia - anastrozols - apvalkotā tablete - 1 mg
anastrozole-teva 1 mg apvalkotās tabletes
teva pharma b.v., netherlands - anastrozols - apvalkotā tablete - 1 mg
anastrozole actavis 1 mg apvalkotās tabletes
actavis group ptc ehf., iceland - anastrozols - apvalkotās tabletes - 1 mg
anastrozole elvim 1 mg apvalkotās tabletes
elvim, sia, latvia - anastrozols - apvalkotā tablete - 1 mg
arimidex 1 mg apvalkotās tabletes
astrazeneca uk limited, united kingdom - anastrozols - apvalkotās tabletes - 1 mg
anastrozolo teva 1 mg apvalkotās tabletes
teva italia s.r.l., italy - anastrozols - apvalkotā tablete - 1 mg
fulvestrant stada 250 mg šķīdums injekcijām pilnšļircē
stada arzneimittel ag, germany - fulvestrants - Šķīdums injekcijām pilnšļircē - 250 mg/5 ml
faslodex
astrazeneca ab - fulvestrant - krūts audzējs - endokrīnās terapijas, anti-estrogēnu - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , pirms vai perimenopausal sievietes, kombinējot ārstēšanu ar palbociclib būtu jāapvieno ar luteinizējošais hormona atbrīvojošo hormonu (lhrh) agonistu.